Eli Lilly announced plans to invest an additional $450M and create at least 100 new jobs to expand its manufacturing capacity at the company’s Research Triangle Park facility. The expansion includes additional parenteral filling, device assembly and packaging capacity to support an increased demand for Lilly’s incretin products that treat diabetes. Since 2020, Lilly has committed roughly $4B to new manufacturing facilities in North Carolina, including $1.7B for the development and expansion of its site at Research Triangle Park. The company anticipates initial production at Research Triangle Park to begin this year, with preparations for inspections by the FDA ongoing.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LLY:
- Eli Lilly, Boehringer: FDA accepts sNDA for Jardiance for adults with CKD
- Donanemab CRL a ‘positive headline’ for Biogen’s Leqembi, says William Blair
- Eli Lilly (NYSE:LLY) Faces Setback in Alzheimer’s Drug Approval
- Eli Lilly discloses FDA complete response letter for submission of donanemab
- California AG files suit against drugmakers, PBMs over insulin prices